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Abstract 
Background: Cancer vaccines can effectively establish clinically relevant tumor immunity. Novel sequencing 
approaches rapidly identify the mutational fingerprint of tumors, thus allowing to generate personalized tumor vac-
cines within a few weeks from diagnosis. Here, we report the case of a 62-year-old patient receiving a four-peptide-
vaccine targeting the two sole mutations of his pancreatic tumor, identified via exome sequencing.
Methods: Vaccination started during chemotherapy in second complete remission and continued monthly thereaf-
ter. We tracked IFN-γ+ T cell responses against vaccine peptides in peripheral blood after 12, 17 and 34 vaccinations 
by analyzing T-cell receptor (TCR) repertoire diversity and epitope-binding regions of peptide-reactive T-cell lines and 
clones. By restricting analysis to sorted IFN-γ-producing T cells we could assure epitope-specificity, functionality, and 
 TH1 polarization.
Results: A peptide-specific T-cell response against three of the four vaccine peptides could be detected sequentially. 
Molecular TCR analysis revealed a broad vaccine-reactive TCR repertoire with clones of discernible specificity. Four 
identical or convergent TCR sequences could be identified at more than one time-point, indicating timely persistence 
of vaccine-reactive T cells. One dominant TCR expressing a dual TCRVα chain could be found in three T-cell clones. The 
observed T-cell responses possibly contributed to clinical outcome: The patient is alive 6 years after initial diagnosis 
and in complete remission for 4 years now.
Conclusions: Therapeutic vaccination with a neoantigen-derived four-peptide vaccine resulted in a diverse and 
long-lasting immune response against these targets which was associated with prolonged clinical remission. These 
data warrant confirmation in a larger proof-of concept clinical trial.
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Background
Pancreatic cancer represents an aggressive cancer 
entity with high morbidity and mortality—especially 
for patients with advanced and metastatic diseases. The 
overall 5-year survival probability is less than 5% [1–4]. 
Therefore, novel therapeutic options are urgently needed. 
Within the past decade, enthusiasm of using vaccines as 
anticancer agents has revived. Data collected so far docu-
ment that a variety of anticancer vaccines including cell-, 
DNA-, and purified component-based vaccines are capa-
ble of circumventing the poorly immunogenic and highly 
immunosuppressive nature of most tumors and eliciting 
therapeutically relevant immune responses [5, 6]. Various 
lines of evidence suggest that pancreatic adenocarcinoma 
can also induce anti-tumoral T-cell responses [7–9], thus 
“off-the-shelf” peptide vaccines (KRAS, Gastrin G17DT, 
HSP-CC-96, WT1, VEGF-R and2, hTERT, Her2/neu, 
KIF20A [10]), recombinant vaccines (MUC-1- and CEA-
expressing poxviruses with GM-CSF), live attenuated 
Listeria mesothelin-expressing vaccines, irradiated whole 
allogenic tumor and Listeria [11], as well as inactivated 
whole tumor cell vaccines (Algenpantucel-L, allogeneic 
GM-CSF) have been evaluated for therapy in this type 
of cancer [12–14]. Preliminary studies yielded promising 
results, yet could not demonstrate significant improve-
ment of patient survival. Nevertheless, they emphasized 
several critical aspects for the design of successful next-
generation cancer vaccines, namely: (i) cancer vaccines 
should target tumor-specific antigens not expressed on 
healthy tissue, (ii) the applied adjuvant should potently 
activate antigen-presenting cells (APCs) which in turn 
stimulate antigen-specific cytotoxic T lymphocytes 
(CTLs) [15], and (iii) vaccine schedules should include 
strategies for breaking immunological tolerance.
Non-self-antigens like unique neo-antigens created by 
tumor specific mutations have hitherto been cumber-
some to detect. The laborious search for tumor-specific 
mutations including cDNA expression cloning, sero-
logic analysis of recombinant cDNA expression libraries 
(SEREX), and reverse immunological approaches [16] 
was dramatically simplified with the advent of next-gen-
eration sequencing (NGS) technologies. Entire cancer 
exomes can be sequenced and compared with healthy 
tissue (germline) exome, providing the fundamentally 
new opportunity to cover the patient’s individual aber-
rancy within a personalized vaccine. Such an approach 
integrates the tremendous heterogeneity of tumors and 
increases the probability of generating a tumor-specific 
immune response, since T cells theoretically should 
bind with a higher affinity to neo-antigens that have not 
been subject to thymic negative selection. In this con-
text, oncogenic driver mutations are not necessarily 
tumor-rejecting antigens [10, 17, 18], and therapeutically 
useful targets may be generated from individual passen-
ger mutations as well [19].
As the induction of cell-mediated immunity requires 
antigen-presentation by activated professional antigen-
presenting cells (APCs) [20], vaccines must be adminis-
tered in conjunction with adjuvants such as incomplete 
Freund’s adjuvant, diverse TLR agonists, alum, or immu-
nostimulatory cytokines such as GM-CSF. In the present 
study GM-CSF was chosen, since it boosted the vaccine 
efficiency in the first licensed cancer vaccine Provenge 
[21], and improved patient outcome in phase 3 studies 
when applied in combination with suitable anti-tumor 
vaccines [22].
Considerable progress towards enhancing vaccine effi-
cacy has been achieved by combining anti-cancer vac-
cines with a varied panel of therapeutics, aiming to break 
the immune-suppressive nature of the tumor milieu 
[23]. Among those agents working synergistically with 
immune interventions are diverse inhibitors of check-
point molecules, targeted and/or chemo-therapies that 
can induce immunogenic cell death (ICD) [5, 23–25]. 
One of those compounds is oxaliplatin, a platinum deriv-
ative and part of the Folfirinox regimen (fluorouracil/
leucovorin, irinotecan, oxaliplatin), a drug combination 
frequently used in the treatment of pancreatic cancer 
[26, 27]. This regimen combines agents that stimulate 
the release of danger signals, upregulates cellular tumor 
antigens, and induces ICD [23]. In addition, oxaliplatin 
reduces the expression of PD-L2, thus enhances antigen-
specific proliferation and Th1 cytokine secretion [28], 
while 5-FU induces apoptosis selectively in MDSC and 
attenuates  Treg activity. Therefore, the Folfirinox regimen 
may induce synergies with immunotherapy by neutraliz-
ing immunosuppression and fueling neo-antigen-specific 
immunity [29–31].
Here, we characterize the T-cell response of a patient 
receiving a 4-peptide-vaccine targeting the two sole 
mutations of his tumor in an individual patient treatment 
approach. Our data show the ability of vaccine-peptides 
to elicit antigen-specific immunity against pancreatic 
carcinoma antigens. We demonstrate the broadness of 
the induced T-cell repertoire, its persistence and modu-
lation over time, as well as novel aspects of vaccine-
induced T-cell responses.
Methods
Patient data
A 62  year old male patient was diagnosed with pan-
creatic ductal carcinoma in September 2011 and 
subsequently underwent pylorus-preserving duodeno-
cephalo-pancreatectomy in October 2011. According 
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to UICC TNM nomenclature the tumor was classified 
as an incompletely resected (R1), poorly differenti-
ated ductal adenocarcinoma Stage IIB, pT3pN1M0. 
According to standard treatment guidelines the patient 
received 6 cycles of Gemcitabine. Six months later 
(7/2012), a metastasis in the liver was diagnosed and 
probed, yet not surgically resected. Subsequently, sec-
ond line chemotherapy was started 9/2012 with applica-
tion of the Folfirinox regimen. 10 months later (7/2013), 
after 19 cycles of Folfirinox, the patient was radiologi-
cally in second complete remission, the tumor marker 
CA19-9 had returned to normal range and therapeutic 
vaccination with tumor-specific peptides was initiated. 
Vaccine induction regimen consisted of five peptide 
vaccinations combined with GM-CSF (Leukine, Berlex, 
Berlin, Germany) as an adjuvant on days 1, 3, 7, 14 and 
28, followed by monthly vaccine boosts. No vaccine-
related adverse events were observed. Folfirinox chemo-
therapy continued in parallel for another 7 cycles until 
January  2014 and was finally halted after a total of 26 
cycles. Peptide vaccination is currently ongoing. The 
patient has been in complete remission (CR) for more 
than 4  years, i.e. 6  years after diagnosis. Time line of 
events is detailed in Fig. 1.
The patient gave his written informed consent for the 
collection of blood and tissue samples and additional 
consent was obtained for using this approach also for 
investigational purposes based on a biospecimen utiliza-
tion protocol.
Staging, surgical resection, diagnostic procedures 
and adjuvant chemotherapy was applied according to 
standard treatment algorithms. Molecular work-up of 
the liver metastasis, peptide design and manufacturing 
was commissioned to commercial service providers by 
the patient. Peptide injections were carried out by the 
patient’s general practitioner.
Identification of neo‑antigens and peptide design
Genomic DNA was isolated from a liver metastasis 
biopsy of the pancreatic carcinoma and a blood sam-
ple of the patient (reference tissue). The samples were 
enriched for whole exome sequencing (Agilent In-Solu-
tion Technology) and sequenced on a SOLiD 5500xl next 
generation sequencing platform (Applied Biosystems/
Life Technologies now Thermo Fisher Scientific). The 
sequence information derived from the tumor tissue was 
bioinformatically compared with the sequence informa-
tion derived from the reference tissue. The called variants 
were then reviewed manually. One missense variant was 
identified, namely within the RIM1-Gene, c.[402G > A], 
p.[Met134Ile] (according to NM_024945). Gene expres-
sion analysis of the altered sequence on mRNA level was 
performed for verification (RNA isolation from fresh fro-
zen tissue). A second mutation with ambiguous quality 
was found in the KIF4B-Gene. Since this mutation also 
represents a potential anti-tumor target, this variant was 
also used for neo-epitope delineation.
For the design of vaccine peptides, epitope prediction 
was performed with the HLA class I peptide binding algo-
rithms NetMHC [32, 33] and SYFPEITHI [34] (Table 1). 
Two peptides—predicted to bind to the patients HLA 
class I—were designed for each neo-sequence by laying 
a virtual 9 amino acid frame onto the respective mutated 
sequence. 2 peptides differing from one another in the 
5′ and 3′ end, respectively (Fig.  2) were chosen for vac-
cination purposes according to optimum likelihood to be 
presented by the patients HLA ligands (A01:01, A02:01; 
B18:01, B44:02; C07:01, C05:041, DRB1 11:01, DRB1 
13:01 DQB1 03:01, DQB1 06:03) Peptide 1:  RMI1127–136 
epitope (WEAKPSRIL), peptide 2;  KIF4B736–747 epitope 
(GIAARVKNWL), peptide 3;  KIF4B738–748 epitope 
(KEGIAARVKNW), and peptide 4;  RMI1128–136 epitope 
(EAKPSRILM)).
Fig. 1 Clinical course of patient’s disease: time line of diagnoses and tumor staging, begin of treatment initiation (yellow block: polychemotherapy, 
red block: anti-tumor peptide vaccine) and time points of immune monitoring
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Application of the vaccine
Vaccination regimen started with a priming phase by 
vaccinating the patient on days 1, 3, 8, 15 and 29, and 
then continued by monthly boost vaccines for mainte-
nance. The peptide cocktail was applied intracutaneously, 
the adjuvant GM-CSF (sargramostin 250  µg/injection, 
 Leukine®) was applied subcutaneously.
Vaccination peptide synthesis and vaccine formulation
Vaccination peptides were ordered commercially (Amer-
ican Peptide Company) by the patient. Before injection, 
the lyophilized peptides were dissolved in DMSO (Hybri-
Max, sterile filtered, Sigma-Aldrich) and further diluted 
in water (Aqua ad injectabilia, B. Braun, Melsungen, Ger-
many) to a final concentration of 0.8 mg/ml per peptide 
(400 µg/500 µl vaccination dose per peptide).
Immune monitoring
Enrichment of peptide‑specific T cells
Immune monitoring was carried out at three defined 
time points: IM1 28  weeks, IM2 44  weeks, and IM3 
108 weeks after initiation of peptide vaccines (after hav-
ing received 8, 12 and 28 vaccinations). At the respective 
time points, patient PBMCs from freshly drawn heparin-
ized blood were isolated with Ficoll Isopaque density gra-
dient centrifugation (Pharmacia, Uppsala, Sweden) and 
cultured in RPMI1640 (10% FBS, P/S, Glu) supplemented 
with low dose IL-2 (20U/ml), IL-7 (2 ng/ml) and vaccine 
peptide- (10 µg/ml) or PBS-pulsed (controls) autologous 
feeder cells to bias survival of potentially in vivo primed 
T cells. Fresh medium containing 10% FBS supplemented 
with IL-2 (20U/ml) and IL-7 (2  ng/ml) was provided 
twice per week, whereas peptide stimulus was given only 
at day 7 of culture. At day 12, cells were restimulated with 
peptide-pulsed (10 µg/ml) PBMCs and T cells responding 
to vaccine-peptide stimulus with IFN-γ production were 
isolated 5 h later using IFN-γ Secretion Assay Kit (Milte-
nyi Biotech, Germany) according to the manufacturer’s 
instructions. Isolated cells were analyzed for the com-
plexity of their T-cell receptor repertoire and epitope-
binding region (CDR3 sequence). In IM1, PBMCs were 
stimulated with a pool of all four peptides, in IM2 the 
four vaccine peptides were analyzed separately, in IM3 
cloning experiments were performed which allowed a 
more detailed identification of peptide-specific TCRs. 
CDR3 size spectratyping of unmanipulated peripheral 
T cells and direct sequencing of single prominent peaks 
was performed at all time points. Additional file 1: Fig. S1 
provides an overview of immune monitoring techniques.
Cloning of neo‑antigen‑specific T cells for identification 
of TCR heterodimers
IFN-γ -selected T cells were expanded for 1  week in 
standard RPMI1640 supplemented with IL-7 (10 ng/ml), 
IL-2 (100 U/ml), and IL-15 (10 ng/ml) and subsequently 
cloned following standard limiting dilution procedure 
(0.3 cells in a 96-round-bottom-well with  105 feeder cells 
(80  Gy-irradiated autologous PBMCs). After 3  weeks of 
cloning culture—allogeneic PBMCs from a 9/10 HLA-
matched healthy donor (A02:01, A02:01; B18:01, B44:02; 
C07:01, C05:041; DRB1 11:01, DRB1 13:01; DQB1 03:01, 
DQB1 06:03) were used as peptide-presenting feeder 
cells. T-cell cloning culture was supplemented with 
fresh medium, IL-7 (10 ng/ml), IL-2 (50U/ml), and IL-15 
(10  ng/ml) twice per week and peptide-pulsed feeder 
cells once per week.
Table 1 The binding scores of individual peptides for the patient’s HLA class I and II haplotypes and CD1d
The binding scores of individual peptides for the patient’s HLA haplotypes were determined via NetMHC [32, 33], SYFPEITHI [34], CD1d-binding algorithm according 
to “Castano” (1-4-7 rule) [55] and NetMHCIIpan version 3.1 [35]
Then likelihood for presentation is given as “+” and “−” respectively; SYFPEITHI half max scores regarding MHC class I presentation are given in brackets. Mutations in 
the peptides are indicated by underline
WB weak binder, SB strong binder, NB no binding predicted
Pep‑
tide
Protien 
origin
Peptide 
sequence
MHC 
class I
Net MHC [32, 
33]
Syfpeithi [34] CD1d Castano [55] MHC class II Net MHC II 
pan3.1 [35]
1 RIM1 WEAKPSRIL B*18 WB +(17) CD1d − DRB1*1101 NB
B*44 WB CD1d − DRB1*1301 NB
(WEAKPSRI) B*44 SB +(21) – −
2 KIF4B GIAARVKNWL A*02 NB +(22) CD1d + DRB1*1101 WB
DRB1*1301 WB
3 KIF4B KEGIAARVKNW B*44 WB −(14) CD1d + DRB1*1101 NB
DRB1*1301 NB
(EGIAARVKNW) B*44 SB −(14) CD1d +
4 RIM1 EAKPSRILM A*02 NB −(6) CD1d − DRB1*1101 NB
DRB1*1301 NB
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Peptide specificity of established clones was evaluated 
using peptide-pulsed monocytes from a HLA-matched 
healthy donor. Presenting monocytes had been highly 
enriched by MACS with αCD14 microbeads (Miltenyi 
Biotec; Bergisch-Gladbach,Germany) to prevent donor 
T-cell contamination. IFN-γ production of T-cells 
clones in response to peptide-presenting monocytes 
was quantified by routine intracellular FACS staining 
procedures.
Molecular methods
RNA extraction, cDNA synthesis
RNA was extracted with the RNeasy Mini Kit (Qia-
gen, Hilden, Germany) and reverse transcribed using 
the Superscript III First Strand Synthesis Super Mix 
(Life Technology, Germany) as recommended by the 
manufacturer.
TCR Vα‑ and Vβ‑repertoire spectratyping
TCR repertoire complexity was analyzed by CDR3 size 
spectratyping in 32 (TCRα) and 24 (TCRβ) PCR reactions 
as published previously [36]. Amplified PCR products 
were size-fractionated by capillary gel electrophoresis 
using the ABI model 3130 Genetic Analyzer, and data 
analyzed with GeneMapper v4.0 (Applied Biosystems).
Identification of the epitope‑binding region of TCRs 
from neo‑antigen‑specific T cells
Single peaks in TCRVα- and Vβ-repertoire spectratype 
analysis were subjected to direct sequencing approaches 
for determination of CDR3 amino acid sequences using 
the  BigDye® Terminator v3.1 Cycle Sequencing Kit (Life 
Technologies, Germany). Sequences were read in an 
ABI3130 Genetic Analyzer and matched with IMGT, 
NCBI Blast and Emboss databases.
Furthermore, selected clones were analyzed by flow 
cytometry for TCRVβ expression using the  IOTest® Beta 
Mark Kit (Beckman Coulter, Germany).
Real time PCR
For (quantitative) analysis of cytokine and transcrip-
tion factor expression, perforin-, granzyme B-, class 
I-restricted T cell-associated molecule (CRTAM)- and 
GAPDH-specific primers were used in combination 
with the SYBR Green kit (Promega, USA) in a BioRad 
C1000 Thermal cycler/CFX96 real-time System (Bio-
Rad, Germany). GAPDH was used as reference gene. 
Briefly, cDNA was added to a final volume of 10 μl/reac-
tion containing 1 × SYBR Green PCR Master Mix (Pro-
mega, USA) and 100 nM of each primer. Thermal cycling 
conditions were: denaturation at 95 °C 10 min, 40 cycles: 
95  °C/30′′, 60  °C/30′′ and 72  °C, 1  min for elongation. 
Fig. 2 Structure of peptides covering neo- versus wild-type epitopes. Tumor-specific single nucleotide polymorphisms (orange) identified with 
NGS technology in the proteins RMI1 and KIF4B. Two 9-mer peptides were designed per tumor specific SNP, each peptide spanning the respective 
mutated sequence, yet varying at the N-terminus. Structural differences between normal (yellow) and tumor specific peptide (blue) are shown in 
3D, generated with IMTEC and UCSF chimera
Page 6 of 13Sonntag et al. J Transl Med  (2018) 16:23 
Primer sequences were: CRTAM-for: 5′-CCTCTCAAG 
ACCCACAGCAG-3′, CRTAM-rev: 5′-AATGAGGA 
A-GGACACCAGCG-3′, perforin-for, 5′-ACCAGCAAT 
GTGCATGTGTCTG-3′ and perforin–rev: 5′-GGCCC 
TCTTGAAGTCAGGGT-3′ [37], GrzB for: 5′-TTCGTGC 
TGA-CAGCTGCTCACT-3′ and GrzB-rev, 5′-CTCTC-
CAGCTGCAGTAGCA-TGA-3′ [38], GAPDH-for: 
5′-CCACATCGCTCAGACACCAT-3′ and GAPDH-rev: 
5 ′-G G C AAC AA-TATCC AC T T TACC AGAC T-3 ′ 
(RTPrimerDB ID 2053).
Flow cytometry
Cells were stained according to standard procedures 
using the following antibodies (clone, manufacturer): 
PerCP/APC-CD3 (SK7, BD), Vioblue-CD4 (VIT4, Milte-
nyi Biotec Germany), APC-H7-CD8α (SK1, BD), FITC/
APC-CD62L (LT-TD180, ImmunoTools), APC-CD25 
(2A3, BD Pharmingen), PE-CF594-A-CCR7 (150503, 
BD), CD45RO, PE-Cy7-CD45RA (H/100, BD), CD27, 
UV1-A-CD25, APC-CD69 (FN50, Biolegend), CD276, 
UV3-CD28, CD95. Intracellular fixation/permeabiliza-
tion kit (eBioscience) and Brilliant-Violet 785-TNF-α 
(MAb11), PE-IFN-γ (B27) were used for intracellu-
lar cytokine staining according to the manufacturer’s 
instructions. Dead cells were excluded via Alexa Fluor 
350 (Invitrogen) or via Zombie Aqua™ (Biolegend). 
PBMCs were pretreated with FcR Blocking Reagent 
(Miltenyi Biotec) according to the manufacturer’s recom-
mendations. Samples were analyzed on a LSR II or FACS 
Canto II with FACS Diva software (BD Biosciences).
Statistical analysis
Data were analyzed with Prism 6.0 (GraphPad Software, 
Inc) and Student’s t test. P < 0.05 was considered statisti-
cally significant.
Results
Patient data, vaccine application and clinical outcome
After receiving state-of-the-art oncological treatment 
for primary and relapsed pancreatic carcinoma, immu-
notherapeutic interventions were initiated in July 2013 
when routine staging (sonography, CT-scan, MRI) did 
not show any residual tumor, neither at the primary nor 
at the metastatic site (second complete remission). The 
tumor was found to be positive for CA19-9 and blood 
levels correlated with the disease course. CA19-9 levels 
have remained within normal ranges since March 2013. 
Chemotherapy was terminated 27  months after disease 
onset (Fig. 1). Currently, 64 months after initial diagno-
sis and 43 months after initialization of vaccine therapy, 
the patient is in good health and fully active (ECOG 0). 
The latest routine examination (physical examination 
and laboratory test in March 2017, CT in Jun 2016 and 
sonography in November 2016) showed no evidence of 
disease.
Overall TCR repertoire complexity increases 
during vaccination
TCRVα and Vβ-chain repertoires of the unmanipulated 
peripheral T-cell pool at IM1 showed a reduced complex-
ity most likely as a consequence of long-term chemo-
therapy. Numerous families in both the TCRVα and Vβ 
chain repertoires, exhibited profound skewing indicat-
ing limited diversity and clonal expansions. Accordingly, 
TCRVα 8-1, 14DV4, 21, 30, and TCRVβ 6-5, 12-3, 21-1 
sequences—obtained by direct sequencing of singular 
peaks (Additional file  2: Fig. S2)—showed CDR3 motifs 
similar to published TCRs specific for CMV (TCRVα 
8-1, 30, TCRVβ 12-3, 21-1) (Table  2) and mycolic acid 
(TCRVβ 6-5) (a cell wall component of several bacteria 
including mycobacterium tuberculosis) and thus can be 
regarded as public TCR motifs [39–41].
Since the patient had no documented infection with 
CMV or mycobacteriaceae at that time, detection of 
these public TCRs rather reflects past infectious epi-
sodes with these microorganisms, which become more 
prominent with increasing age and under lymphode-
pleting chemotherapy [42]. The overall complexity of 
the TCRVα and Vβ chain repertoires slightly increased 
over time after cessation of Folfirinox (Fig. 3).
Detection of vaccine‑reactive T cells at IM1
To test whether the priming phase of the vaccine has 
resulted in a detectable vaccine-reactive T-cell response, 
PBMCs drawn 28  weeks after initiation of vaccina-
tion (i.e. after 8 vaccines) were cultivated ex vivo in the 
presence of vaccine peptides and low dose IL-2, in the 
absence of a mitogen. Such limiting growth conditions 
only activate and expand memory T cells since memory 
T cells have an increased sensitivity for TCR stimulation, 
are more sensitive to low doses of antigen and have an 
increased proliferative potential even without exces-
sive support of cytokines [43]. Moreover, the number 
of mature dendritic cells that is necessary to efficiently 
stimulate and prime naïve T cells in context with costim-
ulatory molecules is low in PBMCs thus naïve T cells get 
stimulated simply with their cognate antigen alone, which 
makes them refractory to further stimulus, hyporespon-
sive and anergic [44, 45]. Thus the short term culture 
protocol impedes in vitro priming of naïve T cells, which 
could lead to false positive results. After expansion and 
restimulation, a total of 1.6% of T cells were responsive 
to the peptide pool with IFN–γ+ production, indicating 
a peptide-specific response (Fig.  4a). Interestingly, the 
majority of responding T cells were  CD4+ (67.5%), the 
remaining  CD8+ (19.7%) or double negative (Fig. 4a).
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Table 2 CDR3 sequences before short term culture and CMV specific CDR3 sequences
CDR3 sequences obtained by direct sequencing of dominant, singular peaks in CDR3 size spectratyping of peripheral T cells that seemed to dominate the TCR 
repertoire without prior stimulation of expansion. Public, CMV-specific CDR3 sequences published previously by Zvyagin et al. are marked in grey [39]
Seq. ID Vαfamily Jαsegm. Vαseq    CDR3seq            Jαseq Seq. ID Vβ family Dβsegm. Jβsegm Vβ seq CDR3seq Jβ seq
1st IM 1 8-1 40 CAV KTG GTYKYIF PMID:19017975 5 6-5 D1 2-7 CASS EDRD YEQYF
2 14DV4 36 CAMRE G TGANNLFF 6 12-3 - 1-5 CASS PNY SNQPQHF PMID:21555537
3 21 44 CAV TRT GTASKLTF 7 21-1 D2 1-2 CASS TRG YGYTF PMID:19017975, 23267020
4 30 40 CGTE IVG GTYKYIF PMID:24711416 8 27-1 D1 2-7 CASSF TLAG EQYF
2nd IM 9 8-1 40 CAV KTG GTYKYIF PMID:19017975 13 6-5 D1 2-7 CASS EDRD YEQYF
10 14DV4 36 CAMRE G TGANNLFF 14 12-3 - 1-5 CASS PNY SNQPQHF PMID:21555537
11 21 44 CAV TRT GTASKLTF  15 21-1 D2 1-2 CASS TRG YGYTF PMID:19017975, 23267020
12 30 40 GTE IVG GTYKYIF PMID:24711416
3rd IM 17 8-1 40 CAV KTG GTYKYIF PMID:19017975 21 2 D2 2-4 CASS SPDYS KNIQYF
18 14DV4 36 CAMRE G TGANNLFF 22 6-5 D1 2-7 CASS EDRD YEQYF
19 21 44 CAV TRT GTASKLTF  23 12-3 - 1-5 CASS PNY SNQPQHF PMID:21555537
20 30 40 GTE IVG GTYKYIF PMID:24711416 24 21-1 D2 1-2 CASS TRG YGYTF PMID:19017975, 23267020
25 25-1 D2 2-5 CASSE RGF QETQYF
26 27-1 D1 2-7 CASSF TLAG EQYF
TCR α  chain TCR β   chain
Before short term culture 
Public motif acording 
to reference
Public motif acording to 
reference
Vβ family Jβsegm. Vβ seq CDR3seq Jβseq MHC allele for isolation Antigen protein Antigen peptide Reference
1* 27 2-1 CASS    KTGGSP     YNEQFF A*02:01 pp65 NLVPMVATV PMID:19017975
2* ND 1-2 CASSL             GGSPNYGYTF B*07:02 pp65 TPRVTGGGAM PMID:21555537
3a* 2 1-1 CA     NTRGE           NTEAFF A*02:01 pp65 NLVPMVATV PMID:19017975
3b* 2-4 2-1 CAS  GRGTGTRGR              NEQFF B*07 pp65 TPRVTGGGAM PMID:23267020
4* 12-3, 12-4 2-2 CAS     AIVG                   ELFF A*02:01 pp65 NLVPMVATV PMID:24711416
CMV specific CDR3 sequences 
Vaccine peptides contribute differently to the T‑cell 
response, IM2
Immune monitoring at time point IM2 (44  weeks after 
initial vaccination) was designed to discriminate how 
the 4 vaccine peptides contributed to the induced T-cell 
response. This time, PBMCs were stimulated with every 
single peptide in short term pre-cultures separately. Pep-
tide 1 boosted the biggest share of IFN-γ+ T cells (0.3% 
IFN-γ+ cells/CD3+), followed by peptide 2 (0.2% IFN-γ+ 
cells/CD3+), whereas peptide 3 and 4 showed responses 
only around the background level (each 0.1% IFN-γ+ 
cells/CD3+) (Fig.  4b). This demonstrates that vaccine 
peptides were able to induce specific T-cell immunity yet 
quantitatively differed in their ability. Of note, peptides 
1 and 2 had higher SYFPEITHI scores for HLA A*02:01 
and B*44:02 than peptides 3 and 4 (Table 1). Only peptide 
2 was also predicted as a binder for HLA DRB1*1101 and 
HLA DRB1*1301 (Table  1). Again, IFN-γ+ T cells were 
largely  CD4+ dominated except for peptide 1 responding 
T cells, which—quite unexpectedly—were mostly (70%) 
CD4-/CD8-double negative (DN) T cells. γδ T cells–T 
cells that belong to innate immunity—lack a coreceptor 
and without the restriction for HLA presentation can 
directly respond to epitopes in proteins in either three 
dimensional as well as linear unfolded form, and also to 
soluble proteins or small peptide antigens [46]. Intrigu-
ingly, the Tetanus toxin-derived peptide Clostridium 
tetani1235–1246 (GNAFNNLDRILR), for which γδ TCR-
dependent responses have been reported [47], shares a 3 
amino acid motif with the vaccine peptide WEAKSPRIL. 
This motif length is sufficient in size to provoke a TCR 
mediated γδ T cell peptide response [48]. Therefore it is 
legitimate to assume that the DN T cells responding to 
peptides are γδ T cells.
Molecular characterization of peptide‑specific T cells, IM1‑3
In order to molecularly characterize the T-cell response 
against the vaccine on the CDR3 sequence level, we puri-
fied IFN-γ-responsive T-cells from IM1 and IM2 after 
expansion and restimulation in short-term culture via an 
IFN-γ-capture assay. These putatively peptide-specific T 
cells were then subject to CDR3 size spectratyping, direct 
sequencing of prominent peaks and bioinformatic data 
analysis. Since the genetic material obtained in this way 
was very limited and precluded more in-depth analyzes, 
at IM3 we generated T-cell clones against the 4 peptides 
using pre-clonal stimulation, IFN-γ-capture, limiting 
dilution and subsequent clonal expansion. Peptide 1 fos-
tered 19 clones, peptide 2 8 clones, peptide 3 1 clone, no 
clone could be obtained with peptide 4. Vaccine-peptide 
specific clones were cultivated for another 3  weeks to 
obtain sufficient numbers for further analysis. Finally, 10 
clones could be harvested in sufficient numbers for fur-
ther analysis (Table 3 lower panel).
T-cell clones were exclusively  CD4+ (Fig. 4c), enriched 
for IFN-γ responsiveness upon restimulation with the 
cognate peptide (Fig.  4c, d) and yielded unequivocally 
singular peaks in CDR3 size spectratypes (not shown). 
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Phenotypically, T-cell clones expressed high levels of 
activation markers such as CD25, CD69, and HLA-DR 
(Additional file  3: Fig. S3), and higher mRNA levels of 
granzymeB, perforin, and CRTAM—that determines the 
CD4+ cytotoxic T lymphocyte lineage [49]—than clones 
established in control cultures without peptide (Fig. 4e). 
Interestingly, the vast majority of T-cell clones in control 
cultures carried the identical public TCR Vα39  Vβ6-2, 
known to be specific for mycolic acid [41], (Additional 
file 4: Fig. S4), suggesting a high precursor frequency in 
peripheral blood and a significant survival advantage for 
these T-cells under the given culture conditions. Vac-
cine-peptide specific T cells were negative for Foxp3 and 
displayed a terminally differentiated effector T cell phe-
notype  (TEMRA,  CCR7−,  CD45RA+) (Additional file  5: 
Figure S5a) [50]. In contrast, clones obtained from con-
trol cultures without peptide exhibited an effector mem-
ory phenotype  (CD45RO+,  CD45RA−,  CD62L−,  CCR7−, 
 CD27−) (Additional file 5: Figure S5b).
The epitope-binding CDR3 regions of the identified 
TCRs were of rather short length (median of 3 N-nucle-
otides, Table 3) and positively charged with the exception 
of TCRs reactive to peptide 1. We were able to identify 
two TCR sequences, with identical TCRVα- and TCRVβ-
derived CDR3 sequences at two time points indicat-
ing persistence of vaccine-specific T-cell responses: 
TCRVβ18 bearing seqID 68 (IM2) and clone 17 (IM3), 
as well as TCRVβ14 bearing seqID 69 (IM2) and clone 
42 (IM3). TCRs that share a common intermediate seg-
ment of the CDR3 sequence yet are flanked by different 
V- and J-gene segments are termed convergent CDR3 
formations. Two convergent CDR3 formations could be 
detected at least at two sequential time points: seqID 
31 (IM1) and seqID 46 (IM2), as well as seqID 44 (IM2) 
and clone 42 (IM3), again indicating clonal persistence. 
Whereas the two convergent TCRVα sequences were 
most likely stimulated by peptide 1, the two identical 
CDR3 sequences unexpectedly were stimulated by pep-
tide 3 in IM2 and by peptide 1 and 2 in IM3. Peptides 1 
and 3 are clearly different, yet are both predicted to bind 
to HLA-B44 and show identical amino acids in anchor 
positions 2 (E) and 7 (R) [34]. Hydrophobic peptides 2 
and 3 both bind to CD1d. Peptides 1 and 2 with the high-
est SYFPEITHI scores and NetMHCIIpan predictions 
induced most of the detectable CDR3 sequences and the 
highest number of clones (Table 1).
Three germline encoded CDR3 sequences (i.e. recom-
bination of VD(J) gene segments without addition of 
N-nucleotides) were identified in peptide 2 (Seq. ID 46, 
50) and peptide 1 (Seq. ID 44) (Table 3) pulsed cultures.
Three of four clones (35, 36, and 54) specific for pep-
tide 1 expressed two TCRVα chains combined with one 
TCRVβ chain, respectively (Table  3), whereas peptide 
2 stimulated five clones with singular TCRVα and -Vβ 
chains.
Discussion
Identification of peptide-reactive T cells within the huge 
repertoire of existing TCR sequences of a human individ-
ual remains a major challenge. NGS approaches have sig-
nificantly improved the sensitivity of clonality assays, e.g. 
in monitoring of minimal residual disease of lymphoid 
malignancies [51] or in tracking of known sequences of 
Fig. 3 Complexity score of peripheral blood TCRVα and TCR-Vβ 
repertoire in our patient at the 1st, 2nd and 3rd immune monitor-
ing as well as in healthy controls (HC). The complexity of Vβ- and 
Vα-chain repertoires was determined by counting the number of 
peaks in spectratype analysis. A score of 8 describes a normal CDR3 
size variability of 8–10 peaks per Gaussian curve, a score of 1 refers to 
profiles showing single peak, 0 describes the absence of peaks. The 
overall TCR complexity (complexity score) is the sum of 26 individual 
TCR Vβ- or 34 TCRVα family scores respectively (with a maximum of 
26 × 8 = 208 for the β-, and 34 × 8 = 272 for the Vα families)
(See figure on next page.) 
Fig. 4 Ex vivo peptide stimulation assays of T cells. T cells were pulsed with peptide, expanded and restimulated in short-term in vitro culture. Cells 
were gated on live-cells, lymphocytic fraction,  CD3+ cells. a At IM1, IFN-γ secretion of T cells was measured after stimulation with a peptide cocktail 
containing all four peptides 4. b At IM2, T cells were stimulated with single peptides, including a no-peptide control, respectively. c IFN-γ-secretion 
and phenotype of a T-cell clone (#33) responsive to peptide 1 obtained from peripheral T cells at IM3. d Percentage of cells from clonal populations 
of defined specificity responding to their peptide with IFN-γ+ production. e mRNA expression of granzymeB, perforin and CRTAM in peptide-specific 
clones from IM3 measured by RT-PCR. Expression of the target gene was normalized to expression of human GAPDH. *P < 0.05, **P < 0.01
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hypervariable regions. High-throughput sequencing may 
allow a better estimation of the actual frequency and 
redundancy of T-cell clonotypes, however, it is not suit-
able for deciphering vaccine-induced T-cell responses. 
Monitoring of immune responses after vaccination 
requires the correlation of identified TCR sequences 
with their specificity [52]. Moreover, more in depth 
analyses of peptide-reactive T cells such as the determi-
nation of TCRVα- and Vβ-chain pairing, potential dual 
TCR expression, phenotypic characterization of mark-
ers such as Foxp3 or CRTAM which distinguish different 
functional states of T cells is not possible by using NGS 
approaches alone. In order to circumvent these limita-
tions of large scale, non-supervised TCR sequencing, we 
Table 3 TCRVα and -Vβ CDR3 sequences of peptide-specific T cells at IM1, IM2 and IM3
Vertical brackets mark identical (“i”) or convergent CDR3 formation (“c”), the latter resulting from combination of different variable and joining regions but identical N 
nucleotides coding for the same amino acids
Seq sequence; yellow germline encoded, pink dual TCR(2 Vα chains, 1 Vβ chain), red information of clone IDs but NOT sequence IDs
*Amino acids in the “N” region position in these CDR3 sequences are germline encoded. CDR3 sequences from IFN-γneg cell fraction of IM1 were identical with CDR3 
sequences identified before immune monitoring 1, 2 and 3 (Table 2). CMV specific sequences are marked in grey
Pulsed with Seq. ID Vα Jα Vα        N               Jα Seq. ID Vβ Dβ Jβs Vβ N Jβ
27 6 31 CAL W NNNARLMF 32 21-1 2 1-2 CASS TRG YGYTF
Peptide 1-4 28 10 52 CVV RK TF 33 30 D1 2-7 CAWS AGTD YEQYF
29 12--2 52 CAV RK AGGTSYGKL 34 25-1 D2 2-1 CASS AGGPG FFGPG
30 21 9 CAV RGP GFKTIFGA 35 24-1 D2 2-3 CATSD FPSGV TQYF
31 26--1 20 CIV RVMG SNDYKLSF
31 35 48 CAG RD NFGNEKLTF
Peptide 1- 4 36 8--1 40 CAV KTG GTYKYIF           PMID:19017975 40 6-5 D1 2-7 CASS EDRD YEQYF
37 14DV4 36 CAMRE G TGANNLFF 41 12-3 - 1-5 CASS PNY SNQPQHF PMID:21555537
38 20 22 CAV VKGG GSARQLTF 42 21-1 2 1-2 CASS TRG YGYTF
PMID:19017975, 
23267020
39 30 40 CGTE IVG GTYKYIF           PMID:24711416 43 27-1 D1 2-7 CASSF TLAG EQYF
Pulsed with Seq. ID Vα Jα Vα         N               Jα Seq. ID Vβ Dβ Jβs Vβ N Jβ
Peptide 1 44 34 42 CGA D GSQGNLIF 58 12-3 D2 2-1 CASS RTRVR NEQFF
45 5 35 CA ESIS FGNVLHC 59 7-2 D2 2-7 CASSL ALRRD EQYF
Peptide 2 46 21 12 CAV RD SSYKLIF 60 5-4 D1 2-3 CASSL GQGTT TDTQYF
47 35 49 CAG RL GTGNQFYF 61 12-3 D2 2-1 CASS RTRVR NEQFF
48 12--1 13 CVV TGPGG GYQKVTF 62 18 D1 2-7 CASSP GTGP YEQYF
49 14DV4 34 CAM RAY TDKLIF 63 20 D2 2-7 CSA LRRGL SYEQYF
50 8--4 44 CAV S GTASKLTLV 64 27 1 2-7 CASS FGQF YEQYF
65 28 D2 2-7 CASS FHGTDKG QYF
66 29 D1 1-1 CS ALETGP EAFF
Peptide 3 51 14DV4 34 CAM RAY TDKLIF 67 7 D1 2-6 CASSL GD NEQFF
52 8--4 - CAV HG polyklonal 68 18 D2 1-2 CASS DGA NYGYTF
53 27 32 CAG GG TNKLIF 69 14 - 2-6 CASSQ GW SGANVLTF
54 21 44 CAV TRT GTASKLTF
Peptide 4 55 10 14 CVV  SH SNSGYALNF
56 21 57 CAV ISR GGSEKLVF
Clones specific for clone ID Vα Jα Vα         N               Jα Vβ Dβ Jβs Vβ N Jβ
Peptide 1 42 9-2 45 CALS D SGGGADGLTF 14 - 2-6 CASSQ GW SGANVLTF
35 26-1 12 CIVR SRLT MDSSYKLIF
29DV5 22 CAAS AVR SSGSARQLTF
36 26-1 12 CIVR SRLT MDSSYKLIF
29DV5 22 CAAS AVR SSGSARQLTF
54 26-1 12 CIVR SRLT MDSSYKLIF
29DV5 22 CAAS AVR SSGSARQLTF
Peptide 2 14 8-3 22 CAVG AR GSARQLTF 9 D2 2-1 CASS GGQAS SYNEQFF
15 14DV4 15 CAMRE GYG QAGTALIF D2 2-3 CASSV ARGT STDTQYF
16 23VD6 53 CAAS RG SGGSNYKLTF 12-2 D1 2-2 CAS NPGKGWA GELFF
17 22 23 CAVE GW GGKLIF 18 D2 1-2 CASS DGA NYGYTF
34 29DV5 45 CAAS 25 D1 1-5 CASSE SGTGVK PQHF
Peptide 3 
37 8-3 22 CAVG AR GSARQLTF 9 D2 2-1 CASS GGQAS SYNEQFF
CDR3seq CDR3seq
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focused on tracking defined T-cell responses against neo-
epitope peptides after short pre-culture and expansion 
of patient PBMCs in the presence of vaccine peptides, a 
standard procedure used for the detection of epitope spe-
cific T cells [53]. Only T cells responding to the peptide 
stimulus with IFN-γ release were isolated and used for 
further examination. By relying on IFN-γ production in 
response to a stimulus we could ascertain the specificity 
of these T cells, their functionality and  TH1 phenotype. 
The separation of the peptide-reactive from non-specific 
background T cells allowed the enumeration of unique 
TCRVα and -Vβ sequences, an estimation on the diver-
sity of induced TCR sequences, and tracking of clonal 
persistence over time. The technique of IFN-γ -capture 
assays is widely used for isolation and transfer of antigen-
specific immunity, and T-cells sorted according to their 
IFN-γ secretion have demonstrated to be highly specific 
and functional, even in the clinical setting [54].
Our results demonstrated a discernible TCR-repertoire 
responsive to the vaccine peptides. Besides a consist-
ency of the IFN-γ+ TCR repertoire in terms of net charge 
we detected two identical and two convergent CDR3 
sequences at more than 1 time point, prodding persis-
tent, vaccine-specific immunity. Furthermore, formation 
of convergent sequences against a common target could 
indicate strong immunogenicity of these neoepitope-
derived peptides and indeed, three of these repetitive 
sequences could be attributed to the same peptide motif. 
However, one identical sequence was found in T cells 
reactive for peptide 1 (RMI1 mutation) and peptide 3 
(KIF4B mutation). Whether sharing of the same present-
ing MHC molecule (HLA-B*44) or identical amino acids 
at anchor positions 2 and 7 contributed to this observa-
tion remains unclear. In general, broadness and diversity 
of peptide-reactive repertoires seemed to correspond 
with the MHC class I binding affinity based on SYFPEI-
THI scores [34]: strong binder peptides 1 and 2 yielded 
more CDR3 sequences than weak binder peptides 3 and 
4. Whether peptide presentation via CD1d (binds hydro-
phobic peptides with hydrophobic amino acids at anchor 
positions 1-4-7) [55] played a role for peptides 2 and 3 
presentation was not assessed in our assays. In addition, 
only peptide 2 was also predicted as a weak binder for 
both of the patient’s HLA DRB MHC class II molecules 
(Table  1). This likelihood for being presented by HLA 
class I and II and CD1d goes well with the broadest TCR 
repertoire and a persistent CDR3 sequence motif induced 
by peptide 2.
The majority of identified T cells expressed single 
TCRVα- and -Vβ chains. Moreover, at IM3 we could 
identify a neo-antigen specific dual TCR, consisting of 
two alpha chains paired with one beta chain, in three 
clones. A dual TCR is able to bind two specificities, of 
which one possibly has not undergone thymic selec-
tion [56]. Dual TCRs account for up to 30% of the nor-
mal T-cell repertoire in humans [57, 58] and in mice 
[59–62], and are regarded as rather beneficial for the 
host since they may help to generate more vigorous 
responses to problematic antigens [63]. Dual TCRs can 
endow T cells with an intrinsic property for alloreactiv-
ity but do not necessarily confer increased susceptibil-
ity for autoimmunity [64]. Interestingly, dual TCRs have 
been described as one of two possible mechanisms by 
which  CD4+ T cells expressing a nominally MHC class 
I-restricted TCR can develop [65]. As a matter of fact, 
although class I restricted peptides were used in this 
study, the vaccine-responsive T cells were mainly  CD4+ 
and expressed CRTAM whose intracellular signaling is 
required for the induction of  CD4+ CTLs [49].  CRTAM+ 
 CD4+ T cells have been described to possess charac-
teristics of both  CD4+ and  CD8+ T cells, secrete IFN-γ, 
exhibit a CTL-related gene signature, such as eomeso-
dermin (Eomes), granzymeB, and perforin, and traffic to 
sites of inflammation [49]. Thus, our data indicate that 
 CD4+ CTLs may play a role in vaccine-induced TCR rep-
ertoires, a finding that warrants further investigation in 
other vaccine settings as well as in preclinical models.
From a clinical perspective, the patient continues to 
show a remarkable long complete remission after stand-
ard therapy for a metastasized pancreatic ductal carci-
noma. Since the patient was already in second complete 
remission when the neoepitope-derived vaccine was 
initiated, we cannot draw definite conclusions whether 
and to what extent the induced tumor-specific immune 
response contributed to long-term survival. Of note, 
induction of the immune response and the ongoing 
remission was achieved without adverse events from 
the vaccine, a frequent finding with therapeutic vac-
cines. In contrast, checkpoint inhibitors like CTLA-4 or 
PD-L1, which may boost but cannot induce anti-tumor 
immune responses, are frequently associated with signifi-
cant adverse events, which can be dose limiting [66]. The 
important question, whether checkpoint blockade could 
enhance vaccine-induced immune responses has to be 
addressed in further clinical trials.
Conclusions
We report a remarkable long-term remission in a patient 
with advanced pancreatic cancer, who received an indi-
vidualized four peptide vaccine based on in silico pre-
dicted peptide motifs from the two sole mutations in 
his cancer, i.e. in the proteins RIM1 and KIF4B. Mod-
erate to strong cytoplasmic and/or nuclear expression 
of these proteins has been documented in pancreatic 
cancer before [67]. Three of the four peptides elicited 
detectable IFN-γ+ CTL responses which were  CD4+ 
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dominated. On the molecular level, both transient and 
persistent peptide-specific TCR CDR3 sequences could 
be identified. Our data show that an individualized, 
neoepitope-derived therapeutic vaccine is able to induce 
a tumor-specific immune response with a traceable 
molecular signature. This detailed immune monitoring 
program covering functional and molecular aspects of 
T-cell biology provides deepened insight into the mecha-
nisms driving cancer vaccine responses and emphasizes 
the potential of personalized vaccines as a promising 
therapeutic strategy in maintaining long-term remis-
sions, which have to be tested in controlled clinical trials.
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